Revision [328]

Last edited on 2009-12-11 02:11:25 by JasonD
Additions:
The study, reported in the August 1 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, was designed to demonstrate the safety and immunogenicity of the vaccine, called modified vaccinia Ankara-encoding 5T4 (""TroVax""?), when used alongside standard chemotherapy. The research was funded by Oxford ""BioMedica"" which is developing the vaccine in partnership with Sanofi-Aventis.
Unlike preventative vaccines, such as the human papillomavirus vaccine to prevent cervical cancer, ""TroVax"" is a therapeutic vaccine, designed to stimulate the immune systems of patients who already have cancer. The vaccine consists of an attenuated (non-disease causing) version of the vaccinia virus modified to deliver the gene for 5T4, a protein found in many tumors.
"The idea is that the modified virus enters cells, produces the tumor protein and stimulates the immune system," said lead study author Richard Harrop, Ph.D., vice president of clinical immunology at Oxford ""BioMedica"". "To give a vaccine alongside chemotherapy might seem counterintuitive, since chemotherapy can weaken the immune system, but our study shows that ""TroVax"" could be complementary to standard chemotherapy, enhancing the immune response to tumors."
"Typically, the immune system doesn't pay attention to this molecule, so by producing 5T4 artificially in combination with the 'danger signals' associated with a viral infection, we are demanding that the immune system take notice," Harrop said. """TroVax"" causes cells at the injection site to produce 5T4 in a way which agitates the immune system into producing antibodies and killer T cells. It is hoped that these two components of the immune system then migrate to tumors and kill them without harming any normal tissues."
Through the course of the study, the researchers monitored the patients for an immune response to 5T4. Eleven of the 17 patients who received the complete course of vaccinations (six injections) mounted strong immune responses to the 5T4 tumor protein. Of these 11 patients, six exhibited significant shrinkage of their tumors and one patient no longer had any detectable tumors. Researchers noted no complications stemming from ""TroVax"" vaccination or any other evidence that would call into question the safety of the vaccine.
Deletions:
The study, reported in the August 1 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, was designed to demonstrate the safety and immunogenicity of the vaccine, called modified vaccinia Ankara-encoding 5T4 (TroVax?), when used alongside standard chemotherapy. The research was funded by Oxford ""BioMedica"" which is developing the vaccine in partnership with Sanofi-Aventis.
Unlike preventative vaccines, such as the human papillomavirus vaccine to prevent cervical cancer, TroVax is a therapeutic vaccine, designed to stimulate the immune systems of patients who already have cancer. The vaccine consists of an attenuated (non-disease causing) version of the vaccinia virus modified to deliver the gene for 5T4, a protein found in many tumors.
"The idea is that the modified virus enters cells, produces the tumor protein and stimulates the immune system," said lead study author Richard Harrop, Ph.D., vice president of clinical immunology at Oxford ""BioMedica"". "To give a vaccine alongside chemotherapy might seem counterintuitive, since chemotherapy can weaken the immune system, but our study shows that TroVax could be complementary to standard chemotherapy, enhancing the immune response to tumors."
"Typically, the immune system doesn't pay attention to this molecule, so by producing 5T4 artificially in combination with the 'danger signals' associated with a viral infection, we are demanding that the immune system take notice," Harrop said. "TroVax causes cells at the injection site to produce 5T4 in a way which agitates the immune system into producing antibodies and killer T cells. It is hoped that these two components of the immune system then migrate to tumors and kill them without harming any normal tissues."
Through the course of the study, the researchers monitored the patients for an immune response to 5T4. Eleven of the 17 patients who received the complete course of vaccinations (six injections) mounted strong immune responses to the 5T4 tumor protein. Of these 11 patients, six exhibited significant shrinkage of their tumors and one patient no longer had any detectable tumors. Researchers noted no complications stemming from TroVax vaccination or any other evidence that would call into question the safety of the vaccine.

Revision [327]

Edited on 2009-12-11 02:09:58 by JasonD
Additions:
In the Nov. 1 issue of the journal Cancer Research, researchers examined human colon and breast cancer cells and established a role of sphingosine kinase 2 (""SphK2""), an enzyme that forms the potent lipid mediator sphingosine-1-phosphate in the death of cancer cells mediated by the chemotherapeutic drug, doxorubicin.
Deletions:
In the Nov. 1 issue of the journal Cancer Research, researchers examined human colon and breast cancer cells and established a role of sphingosine kinase 2 (SphK2), an enzyme that forms the potent lipid mediator sphingosine-1-phosphate in the death of cancer cells mediated by the chemotherapeutic drug, doxorubicin.

Revision [326]

Edited on 2009-12-11 02:09:05 by JasonD
Additions:
According to Spiegel, the study demonstrated that ""SphK2"" is important for p53-independent induction of expression of p21, a cyclin-dependent kinase inhibitor. This p21 regulates the cell cycle, and apoptosis or programmed cell suicide, mediated by doxorubicin. Human colon and breast cancer cells were killed more efficiently by doxorubicin when ""SphK2"" was removed from the cells.
"Therefore, the findings suggest that ""SphK2"" influences the balance between cytostasis, and apoptosis of human cancer cells," Spiegel said. Cytostasis refers to the stoppage of cellular growth and multiplication.
Deletions:
According to Spiegel, the study demonstrated that SphK2 is important for p53-independent induction of expression of p21, a cyclin-dependent kinase inhibitor. This p21 regulates the cell cycle, and apoptosis or programmed cell suicide, mediated by doxorubicin. Human colon and breast cancer cells were killed more efficiently by doxorubicin when SphK2 was removed from the cells.
"Therefore, the findings suggest that SphK2 influences the balance between cytostasis, and apoptosis of human cancer cells," Spiegel said. Cytostasis refers to the stoppage of cellular growth and multiplication.

Revision [325]

Edited on 2009-12-11 02:08:06 by JasonD
Additions:
Amgen (Nasdaq: AMGN) and Abgenix, Inc. (Nasdaq: ABGX) today announced that Amgen has completed the Biologic License Application (BLA) submission with the U.S. Food and Drug Administration (FDA) for Panitumumab. The potential indication is for the treatment of metastatic colorectal cancer in patients who have failed prior chemotherapy, including oxaliplatin and/or irinotecan containing regimens. The rolling BLA submission was initiated in December 2005.
Deletions:
Amgen (Nasdaq: AMGN) and Abgenix, Inc. (Nasdaq: ABGX) today announced that Amgen has completed the Biologic License Application (BLA) submission with the U.S. Food and Drug Administration (FDA) for [[PanitumumabInfo panitumumab]]. The potential indication is for the treatment of metastatic colorectal cancer in patients who have failed prior chemotherapy, including oxaliplatin and/or irinotecan containing regimens. The rolling BLA submission was initiated in December 2005.

Revision [324]

Edited on 2009-12-11 02:06:45 by JasonD
Additions:
A therapeutic cancer vaccine has shown effectiveness when given alongside chemotherapy to patients with metastatic colorectal cancer in a phase II trial, according to researchers at Oxford ""BioMedica"" (UK) Ltd. The study found that six of the 17 metastatic colorectal cancer patients in the study showed tumor shrinkage, classified as complete or partial responses following independent expert review.
The study, reported in the August 1 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, was designed to demonstrate the safety and immunogenicity of the vaccine, called modified vaccinia Ankara-encoding 5T4 (TroVax?), when used alongside standard chemotherapy. The research was funded by Oxford ""BioMedica"" which is developing the vaccine in partnership with Sanofi-Aventis.
"The idea is that the modified virus enters cells, produces the tumor protein and stimulates the immune system," said lead study author Richard Harrop, Ph.D., vice president of clinical immunology at Oxford ""BioMedica"". "To give a vaccine alongside chemotherapy might seem counterintuitive, since chemotherapy can weaken the immune system, but our study shows that TroVax could be complementary to standard chemotherapy, enhancing the immune response to tumors."
Deletions:
A therapeutic cancer vaccine has shown effectiveness when given alongside chemotherapy to patients with metastatic colorectal cancer in a phase II trial, according to researchers at Oxford BioMedica (UK) Ltd. The study found that six of the 17 metastatic colorectal cancer patients in the study showed tumor shrinkage, classified as complete or partial responses following independent expert review.
The study, reported in the August 1 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, was designed to demonstrate the safety and immunogenicity of the vaccine, called modified vaccinia Ankara-encoding 5T4 (TroVax?), when used alongside standard chemotherapy. The research was funded by Oxford BioMedica which is developing the vaccine in partnership with Sanofi-Aventis.
"The idea is that the modified virus enters cells, produces the tumor protein and stimulates the immune system," said lead study author Richard Harrop, Ph.D., vice president of clinical immunology at Oxford BioMedica. "To give a vaccine alongside chemotherapy might seem counterintuitive, since chemotherapy can weaken the immune system, but our study shows that TroVax could be complementary to standard chemotherapy, enhancing the immune response to tumors."

Revision [237]

Edited on 2009-11-21 03:07:14 by JasonD
Additions:
"Our new data indicate that picoplatin can be safely combined with established cancer therapeutics. In 66 patients treated up to 10 months, we have observed reversible myelosuppression that is non-cumulative and has not led to any treatment-related mortality," said Jerry ""McMahon"", Ph.D., chairman and CEO of Poniard. "These Phase 1 studies have explored different doses of picoplatin and different dosing schedules either in combination with docetaxel for prostate cancer or with 5-fluorouracil and leucovorin for colorectal cancer. We anticipate that the Phase 2 trials for both indications will begin in the third quarter of 2007, shortly after the maximum tolerated doses have been defined."
Deletions:
"Our new data indicate that picoplatin can be safely combined with established cancer therapeutics. In 66 patients treated up to 10 months, we have observed reversible myelosuppression that is non-cumulative and has not led to any treatment-related mortality," said Jerry McMahon, Ph.D., chairman and CEO of Poniard. "These Phase 1 studies have explored different doses of picoplatin and different dosing schedules either in combination with docetaxel for prostate cancer or with 5-fluorouracil and leucovorin for colorectal cancer. We anticipate that the Phase 2 trials for both indications will begin in the third quarter of 2007, shortly after the maximum tolerated doses have been defined."

Revision [236]

Edited on 2009-11-21 03:06:23 by JasonD
Additions:
The filing in Japan is a result of a development collaboration between ""ImClone"" Systems, Bristol-Myers Squibb, and
22""KGaA"" of Darmstadt, Germany.
Commenting on the data for an important subgroup of the CRYSTAL trial, which had liver limited disease, Dr Wolfgang Wein, Senior Executive Vice President, Oncology, Merck Serono - a division of Merck ""KGaA"", Darmstadt, Germany said "We are delighted with the results presented at WCGIC. Besides the significant outcomes for the overall population in the CRYSTAL trial we were able to define the patients with the greatest benefit. In patients with metastases limited to the liver 10% of patients had a complete resection of the tumor, which means hope for cure. This was possible because Erbitux significantly increased the tumor response rate".
Deletions:
The filing in Japan is a result of a development collaboration between ""ImClone"" Systems, Bristol-Myers Squibb, and Merck 22""KGaA"" of Darmstadt, Germany.
Commenting on the data for an important subgroup of the CRYSTAL trial, which had liver limited disease, Dr Wolfgang Wein, Senior Executive Vice President, Oncology, Merck Serono - a division of Merck KGaA, Darmstadt, Germany said "We are delighted with the results presented at WCGIC. Besides the significant outcomes for the overall population in the CRYSTAL trial we were able to define the patients with the greatest benefit. In patients with metastases limited to the liver 10% of patients had a complete resection of the tumor, which means hope for cure. This was possible because Erbitux significantly increased the tumor response rate".

Revision [235]

Edited on 2009-11-21 03:05:14 by JasonD
Additions:
The filing in Japan is a result of a development collaboration between ""ImClone"" Systems, Bristol-Myers Squibb, and Merck 22""KGaA"" of Darmstadt, Germany.
Deletions:
The filing in Japan is a result of a development collaboration between ""ImClone"" Systems, Bristol-Myers Squibb, and Merck 22KGaA"" of Darmstadt, Germany.

Revision [141]

The oldest known version of this page was created on 2009-11-07 03:04:46 by JasonD
Valid XHTML :: Valid CSS: :: Powered by WikkaWiki